Consulting on Regenerative Medicine and Contract Cell Culture

「In addition, we provide consulting to providers of regenerative medicine and other medical services and contract manufacturing services for specified cell-processed products in accordance with the Act on the Safety of Regenerative Medicine and Other Products, which came into force in November 2014.」

「Under the Act on the Safety of Regenerative Medicine and Other Products, we provide consulting to providers of regenerative medicine and other medical services, as well as contract manufacturing services for specified cell-processed products.」

「Under the Act on the Safety of Regenerative Medicine and Other Products, we provide consulting to providers of regenerative medicine and other medical services, as well as contract manufacturing services for specified cell-processed products. Our consulting services support the administrative procedures required for clinical research and the provision of treatment, including preparing plans for the provision of regenerative medicine and other medical services and establishing operating systems for cell processing facilities. Under our contract manufacturing service for specified cell-processed products, we accept contracts to manufacture specified cell-processed products at our cell culture and processing facility licensed by the Ministry of Health, Labour and Welfare.」

「Under the Act on the Safety of Regenerative Medicine and Other Products, we provide consulting to providers of regenerative medicine and other medical services, as well as contract manufacturing services for specified cell-processed products.」

「Under the Act on the Safety of Regenerative Medicine and Other Products, we provide consulting to providers of regenerative medicine and other medical services, as well as contract manufacturing services for specified cell-processed products. Our consulting services support the administrative procedures required for clinical research and the provision of treatment, including preparing plans for the provision of regenerative medicine and other medical services and establishing operating systems for cell processing facilities. Under our contract manufacturing service for specified cell-processed products, we accept contracts to manufacture specified cell-processed products at our cell processing facility licensed by the Ministry of Health, Labour and Welfare.」

「We provide consulting to providers of regenerative medicine and other medical services, as well as contract manufacturing services for specified cell-processed products.」

「Under the Act on the Safety of Regenerative Medicine and Other Products, we provide consulting to providers of regenerative medicine and other medical services, as well as contract manufacturing services for specified cell-processed products. Our consulting services support the administrative procedures required for clinical research and the provision of treatment, including preparing plans for the provision of regenerative medicine and other medical services and establishing operating systems for cell processing facilities. Under our contract manufacturing service for specified cell-processed products, we accept contracts to manufacture specified cell-processed products at our cell processing facility licensed by the Ministry of Health, Labour and Welfare.」

「Under the Act on the Safety of Regenerative Medicine and Other Products, we provide consulting to providers of regenerative medicine and other medical services, as well as contract manufacturing services for specified cell-processed products. Our consulting services support the administrative procedures required for clinical research and the provision of treatment, including preparing plans for the provision of regenerative medicine and other medical services and establishing operating systems for cell processing facilities. Under our contract manufacturing service for specified cell-processed products, we accept contracts to manufacture specified cell-processed products at our cell processing facility licensed by the Ministry of Health, Labour and Welfare.」

「Revenue from the regenerative medicine contract business for the cumulative first quarter was ¥124.185 million, up 40.5% year on year. Revenue increased from the same period of the previous year due to milestone income and other revenue associated with advancing contracted projects. In March 2019, Gamagori City Hospital joined the joint research facilities for clinical research treating vitiligo and intractable skin ulcers at Nagoya City University Hospital, enabling us to accept contract manufacturing of cultured epidermis from the hospital from April of the same year.」

「In March 2019, Gamagori City Hospital joined the joint research facilities for this clinical research, and we will proceed with contract manufacturing of the same epidermis for the hospital.」

「Revenue from the regenerative medicine contract business for the cumulative third quarter was ¥473.520 million, up 15.3% year on year. The number of contracted customers increased in response to growing corporate activity in regenerative medicine and other areas. Revenue was also supported by milestone payments received as contracted research projects reached milestones, as well as increased new orders for development consulting and contract development and manufacturing of regenerative medicine products.」

「Revenue from the regenerative medicine contract business for the cumulative second quarter was ¥297.651 million, up 21.3% year on year.」

「Under the Act on the Safety of Regenerative Medicine and Other Products, which came into force in November 2014, we provide consulting to providers of regenerative medicine and other medical services, as well as contract manufacturing services for specified cell-processed products.」

「In July 2017, under the Act on the Safety of Regenerative Medicine and Other Products, we secured contracts from medical institutions and other organisations to manufacture specified cell-processed products, including cultured epidermis for use in clinical research treating vitiligo and intractable skin ulcers at Nagoya City University Hospital. We also newly secured several contracts to support the preparation of treatment provision plans and to provide consulting on the construction and operation of manufacturing facilities.」

「We also proceeded with preparations from July 2017 for contract manufacturing for cultured epidermis transplants at Nagoya City University Hospital for conditions including vitiligo and intractable skin ulcers.」

「Following the enforcement of the Act on the Safety of Regenerative Medicine and Other Products in November 2014, we launched a consulting business for providers of regenerative medicine and other medical services and cell processing and manufacturing operators, as well as a contract cell culture business. In October 2015, we obtained a licence to manufacture specified cell-processed products, establishing the framework to accept cell culture contracts from medical institutions and other organisations.」

「We launched a regulatory compliance consulting business for providers of regenerative medicine and other medical services, as well as cell processing and manufacturing operators, using the expertise we had developed through our regenerative medicine products business. In October 2015, we obtained a licence to manufacture specified cell-processed products and launched a contract cell processing business for medical institutions and other organisations.」